Novel protein helps castration-resistant prostate tumors resist treatment and may be a target
Researchers have identified a mechanism in androgen-insensitive prostate cancer cells that enables them to survive treatment. The research team discovered a protein called Siah2 that keeps a portion of androgen receptors constantly active in these prostate cancer cells. Androgen receptors, which are sensors that receive and respond to the hormone androgen, play a critical role in prostate cancer development and progression.
Prostate cancer that stops responding to hormonal treatment is androgen-insensitive or castration-resistant prostate cancer. The new information means that Siah2 could make a promising biomarker for tracking a prostate cancer patient's response to therapy. Further, inhibiting Siah2's interaction with the androgen receptor complex might also provide a new method for resensitizing castration-resistant prostate tumors to hormone therapy.
"Prostate tumors become castration-resistant by using diverse ways to modify androgen receptor to become constantly active. In this study, we demonstrate how this happens through a previously unknown mechanism orchestrated by Siah2. Surprisingly, it turns out that only a fraction of all androgen receptors are altered in castration-resistant tumors," said Ze'ev Ronai, PhD, associate director of Sanford-Burnham's National Cancer Institute-designated Cancer Center in La Jolla, California, scientific director of the Institute's La Jolla campus, and senior author of the study. The study was published in Cancer Cell (2013; doi:10.1016/j.ccr.2013.02.016).
Normally, androgen receptors are kept in check by an inhibitor called NCOR1. This study revealed that, in castration-resistant prostate tumors, Siah2 tags the NCRO1-androgen receptor complex for degradation. That removes the brake, allowing the recycling of inactive androgen receptor to active status. As a result, prostate cancer cells produce more active androgen receptors, which render them resistant to hormone therapy.
Ronai and colleagues wondered if Siah2 plays the same role in real-life castration-resistant prostate cancer as they had observed in the laboratory. Using samples provided by collaborators at the Vancouver Prostate Centre at the University of British Columbia, the team determined that human castration-resistant prostate tumors have abnormally high levels of Siah2 and select androgen receptor targets. This finding underscores the clinical significance of the castration-resistance mechanism they uncovered.
Ronai and his team also looked at what happens when they inhibit Siah2. To do this, they used three different animal models. In each case, inhibiting Siah2 restored prostate tumors' sensitivity to hormone therapy. With Siah2 out of the picture, prostate tumors regressed during hormone therapy.
"We see Siah2 not only as a biomarker—a way to track the development and progression of castration-resistance—but also as a potential therapeutic target for prostate cancer," explained Jianfei Qi, PhD, staff scientist in Ronai's laboratory and first author of the paper.